Literature DB >> 16316398

Pathophysiology and aetiological diagnosis of inflammatory myocardial diseases with a special focus on parvovirus B19.

S Pankuweit1, V Ruppert, H Eckhardt, D Strache, B Maisch.   

Abstract

Inflammatory processes induced by viral or bacterial infections are believed to be one of the major pathogenetic mechanisms in myocardial diseases. Although the reason for progression to myocardial failure is not fully understood, postulated mechanisms include persistent viral infection alone or in combination with autoimmune processes. A variety of cardiotropic viruses have been identified to elicit myocarditis, with enteroviruses and adenoviruses as the most frequent causative agents in children and adolescents. However, parvovirus B19 (PVB19) has recently emerged as another potential pathogen in adult patients associated with inflammatory heart disease. Many dimensions of inflammatory heart disease coexist while different phases of the disease progress simultaneously: phase 1 is dominated by viral infection, phase 2 by the onset of (probably) multiple autoimmune reactions, and phase 3 by the progression to cardiac dilatation without the role of an infectious agent and cardiac inflammation. Taking these mechanisms into account, screening for viral and bacterial genome by polymerase chain reaction (PCR) and detection of inflammatory infiltrates by immunohistochemistry are considered crucial for establishing an aetiological diagnosis, thereby allowing initiation of specific therapeutic strategies. In a large cohort of 3345 consecutive patients with left ventricular dysfunction evaluated over a period of 10 years, prevalence of PVB19, coxsackievirus (CVB), human cytomegalovirus (HCMV), influenza A virus and adenovirus (ADV) genome was assessed by PCR. Inflammatory infiltrates within the myocardium were detected by immunohistochemistry according to the WHF criteria and by histopathology according to the Dallas criteria of myocarditis. For control, endomyocardial samples of patients with arterial hypertension were studied. Parvovirus B19 was the most often detected virus in all patient subgroups, with positivity ranging from 17% to 33%. Except for PVB19, CVB RNA (3%), ADV (2%) and CMV (3.9%) were the most frequently detected viral genomes. Interestingly, detection of PVB19 genome was significantly correlated with inflammatory heart disease and reduced ejection fraction. Importantly, an aetiological diagnosis requires the immunohistochemical and molecular biological investigation of endomyocardial biopsies. Such an approach may change the management of these diseases in the future. One of the aims of the study was to reveal the underlying dominant pathophysiological mechanisms in a for deciding on the most approriate therapy.

Entities:  

Mesh:

Year:  2005        PMID: 16316398     DOI: 10.1111/j.1439-0450.2005.00873.x

Source DB:  PubMed          Journal:  J Vet Med B Infect Dis Vet Public Health        ISSN: 0931-1793


  6 in total

Review 1.  [Treatment of progressive heart failure: pharmacotherapy, resynchronization (CRT), surgery].

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Herz       Date:  2010-03       Impact factor: 1.443

2.  Parvovirus B19 myocarditis causes significant morbidity and mortality in children.

Authors:  Kimberly M Molina; Xiomara Garcia; Susan W Denfield; Yuxin Fan; William R Morrow; Jeffrey A Towbin; Elizabeth A Frazier; David P Nelson
Journal:  Pediatr Cardiol       Date:  2012-08-08       Impact factor: 1.655

Review 3.  Viral myocarditis: from experimental models to molecular diagnosis in patients.

Authors:  Sabine Pankuweit; Karin Klingel
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 4.  Viral myocarditis: diagnosis, aetiology and management.

Authors:  Uwe Kühl; Heinz-Peter Schultheiss
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

5.  [The heart in viral infections].

Authors:  S Pankuweit; B Maisch
Journal:  Internist (Berl)       Date:  2010-07       Impact factor: 0.743

6.  Takotsubo Syndrome Associated with COVID-19.

Authors:  Elena Roca; Carlo Lombardi; Marco Campana; Oscar Vivaldi; Barbara Bigni; Bruno Bertozzi; Giovanni Passalacqua
Journal:  Eur J Case Rep Intern Med       Date:  2020-04-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.